Efficacy of B-type natriuretic peptide is coupled to phosphodiesterase 2A in cardiac sympathetic neurons

Hypertension

Volumn 66, Issue 1, 2015, Pages 190-198

  Li, Dan ^a   Lu, Chieh Ju ^a   Hao, Guoliang ^a   Wright, Hannah ^a   Woodward, Lavinia ^a   Liu, Kun ^a   Vergari, Elisa ^a   Surdo, Nicoletta C ^a   Herring, Neil ^a   Zaccolo, Manuela ^a   Paterson, David J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

calcium; natriuretic peptide, brain; sympathetic nervous system; synaptic transmission

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; FURA 2 ACETOXYMETHYL ESTER; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2A; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE RECEPTOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; HYBRID PROTEIN; ISATIN; NATRIURETIC PEPTIDE RECEPTOR A; PDE2A PROTEIN, RAT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM CURRENT; CALCIUM SIGNALING; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROPHYSIOLOGICAL PROCEDURES; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE TRANSFER; HEART RATE; IMMUNOASSAY; IN VITRO STUDY; MALE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE GANGLION; STIMULUS RESPONSE; SYMPATHETIC NERVE; SYMPATHETIC NERVE CELL; WESTERN BLOTTING; ADRENERGIC SYSTEM; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEART MUSCLE CONDUCTION SYSTEM; HYPERTENSION; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; SECOND MESSENGER; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION;

ANIMALS; CALCIUM SIGNALING; CELLS, CULTURED; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; HEART CONDUCTION SYSTEM; HEART RATE; HYPERTENSION; ISATIN; MALE; NATRIURETIC PEPTIDE, BRAIN; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RECOMBINANT FUSION PROTEINS; SECOND MESSENGER SYSTEMS; STELLATE GANGLION; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION;

EID: 84942753498     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.05054     Document Type: Article

References (50)

1. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH., Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 2003 57 515 522
2. Tremblay J, Desjardins R, Hum D, Gutkowska J, Hamet P., Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. Mol Cell Biochem 2002 230 31 47
3. Potter LR, Abbey-Hosch S, Dickey DM., Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006 27 47 72. doi: 10.1210/er.2005-0014
4. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M., Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994 89 2232 2240
5. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A., Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004 102 223 241. doi: 10.1016/j.pharmthera.2004.04.004
6. Maruyama K, Shiga T, Iijima M, Moriya S, Mizuno S, Toi S, Arai K, Ashihara K, Abe K, Uchiyama S., Brain natriuretic peptide in acute ischemic stroke. J Stroke.Cerebrovasc Dis 2014 23 967 972. doi: 10.1016/j.jstrokecerebrovasdis.2013.08.003
7. Macheret F, Heublein D, Costello-Boerrigter LC, Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol 2012 60 1558 1565. doi: 10.1016/j.jacc.2012.05.049
8. Lee CY, Burnett JC Jr, Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007 12 131 142. doi: 10.1007/s10741-007-9016-3
9. Chinkers M, Garbers DL, Chang MS, Lowe DG, Chin HM, Goeddel DV, Schulz S., A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989 338 78 83. doi: 10.1038/338078a0
10. Castro LR, Schittl J, Fischmeister R., Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res 2010 107 1232 1240. doi: 10.1161/CIRCRESAHA.110.226712
11. Omori K, Kotera J., Overview of PDEs and their regulation. Circ Res 2007 100 309 327. doi: 10.1161/01.RES.0000256354.95791.f1
12. Sodi R, Dubuis E, Shenkin A, Hart G., B-Type natriuretic peptide (BNP) attenuates the L-Type calcium current and regulates ventricular myocyte function. Regul Pept 2008 151 95 105. doi: 10.1016/j.regpep.2008.06.006
13. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW., Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998 4 37 44
14. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M., Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008 29 1485 1494. doi: 10.1093/eurheartj/ehn206
15. Moltzau LR, Aronsen JM, Meier S, Skogestad J, Ørstavik Ø Lothe GB, Sjaastad I, Skomedal T, Osnes JB, Levy FO, Qvigstad E., Different compartmentation of responses to brain natriuretic peptide and C-Type natriuretic peptide in failing rat ventricle. J Pharmacol Exp Ther 2014 350 681 690. doi: 10.1124/jpet.114.214882
16. Molkentin JD., A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest 2003 111 1275 1277. doi: 10.1172/JCI18389
17. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD., Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001 37 1221 1227
18. Schwartz PJ., Cardiac sympathetic denervation to prevent life-Threatening arrhythmias. Nat Rev Cardiol 2014 11 346 353. doi: 10.1038/nrcardio.2014.19
19. Luchner A, Schunkert H., Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system. Cardiovasc Res 2004 63 443 449. doi: 10.1016/j.cardiores.2004.05.004
20. Chan NY, Seyedi N, Takano K, Levi R., An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation 2012 125 298 307. doi: 10.1161/CIRCULATIONAHA.111.059097
21. Schwarz P, Diem R, Dun NJ, Förstermann U., Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 1995 77 841 848
22. Choate JK, Paterson DJ., Nitric oxide inhibits the positive chronotropic and inotropic responses to sympathetic nerve stimulation in the isolated guinea-pig atria. J Auton Nerv Syst 1999 75 100 108
23. Li D, Wang L, Lee CW, Dawson TA, Paterson DJ., Noradrenergic cell specific gene transfer with neuronal nitric oxide synthase reduces cardiac sympathetic neurotransmission in hypertensive rats. Hypertension 2007 50 69 74. doi: 10.1161/HYPERTENSIONAHA.107.088591
24. Mehel H, Emons J, Vettel C, Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-Adrenergic responses in cardiomyocytes. J Am Coll Cardiol 2013 62 1596 1606. doi: 10.1016/j.jacc.2013.05.057
25. Pardini BJ, Lund DD, Schmid PG., Organization of the sympathetic postganglionic innervation of the rat heart. J Auton Nerv Syst 1989 28 193 201
26. Lugnier C., Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006 109 366 398. doi: 10.1016/j.pharmthera.2005.07.003
27. Bender AT, Beavo JA., Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006 58 488 520. doi: 10.1124/pr.58.3.5
28. Gesellchen F, Stangherlin A, Surdo N, Terrin A, Zoccarato A, Zaccolo M., Measuring spatiotemporal dynamics of cyclic AMP signaling in real-Time using FRET-based biosensors. Methods Mol Biol 2011 746 297 316. doi: 10.1007/978-1-61779-126-0-16
29. Li D, Nikiforova N, Lu CJ, Wannop K, McMenamin M, Lee CW, Buckler KJ, Paterson DJ., Targeted neuronal nitric oxide synthase transgene delivery into stellate neurons reverses impaired intracellular calcium transients in prehypertensive rats. Hypertension 2013 61 202 207. doi: 10.1161/HYPERTENSIONAHA.111.00105
30. Dries DL., Process matters: emerging concepts underlying impaired natriuretic peptide system function in heart failure. Circ Heart Fail 2011 4 107 110. doi: 10.1161/CIRCHEARTFAILURE.111.960948
31. Machowska A, Juszczak K, Novak P, Thor P., The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors-The novel therapeutical approach of hypertension treatment. Folia Med Cracov 2009 50 35 42
32. Bergey JL, Much DR, Kratunis V, Asaad M., Effects of human ANF-(99-126) on sympathetic nerve function, hemodynamic parameters and plasma cGMP levels in anesthetized, ganglion-blocked dogs. Eur J Pharmacol 1989 159 103 112
33. Zeuzem S, Olbrich HG, Haak T, Jungmann E., In vivo evidence that human atrial natriuretic factor-(99-126) (hANF) stimulates parasympathetic activity in man. Eur J Clin Pharmacol 1990 39 77 79
34. Ackermann U, Khanna J, Irizawa TG., Atrial natriuretic factor alters autonomic interactions in the control of heart rate in conscious rats. Can J Physiol Pharmacol 1988 66 930 936
35. Herring N, Zaman JA, Paterson DJ., Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway. Am J Physiol Heart Circ Physiol 2001 281 H2318 H2327
36. Li D, Lee CW, Buckler K, Parekh A, Herring N, Paterson DJ., Abnormal intracellular calcium homeostasis in sympathetic neurons from young prehypertensive rats. Hypertension 2012 59 642 649. doi: 10.1161/HYPERTENSIONAHA.111.186460
37. Kong X, Wang X, Xu W, Behera S, Hellermann G, Kumar A, Lockey RF, Mohapatra S, Mohapatra SS., Natriuretic peptide receptor a as a novel anticancer target. Cancer Res 2008 68 249 256. doi: 10.1158/0008-5472.CAN-07-3086
38. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA., Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000 52 375 414
39. Zhang FX, Liu XJ, Gong LQ, Yao JR, Li KC, Li ZY, Lin LB, Lu YJ, Xiao HS, Bao L, Zhang XH, Zhang X., Inhibition of inflammatory pain by activating B-Type natriuretic peptide signal pathway in nociceptive sensory neurons. J Neurosci 2010 30 10927 10938. doi: 10.1523/JNEUROSCI.0657-10.2010
40. Suvarna NU, O'Donnell JM., Hydrolysis of N-methyl-D-Aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol Exp Ther 2002 302 249 256
41. Hu F, Ren J, Zhang JE, Zhong W, Luo M., Natriuretic peptides block synaptic transmission by activating phosphodiesterase 2A and reducing presynaptic PKA activity. Proc Natl Acad Sci U S A 2012 109 17681 17686. doi: 10.1073/pnas.1209185109
42. Reinecke D, Burhenne H, Sandner P, Kaever V, Seifert R., Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciated. FEBS Lett 2011 585 3259 3262. doi: 10.1016/j.febslet.2011.09.004
43. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC., Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014 13 290 314. doi: 10.1038/nrd4228
44. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M., Compartmentalized phosphodiesterase-2 activity blunts beta-Adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 2006 98 226 234. doi: 10.1161/01.RES.0000200178.34179.93
45. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G., Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004 47 1081 1092. doi: 10.1016/j.neuropharm.2004.07.040
46. Xu Y, Pan J, Chen L, Zhang C, Sun J, Li J, Nguyen L, Nair N, Zhang H, O'Donnell JM., Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway. Int J Neuropsychopharmacol 2013 16 835 847. doi: 10.1017/S146114571200065X
47. Russwurm C, Zoidl G, Koesling D, Russwurm M., Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. J Biol Chem 2009 284 25782 25790. doi: 10.1074/jbc.M109.017194
48. Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, Shirakami G, Arai H, Jougasaki M, Imura H., Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991 69 1500 1506
49. Schroeder EB, Liao D, Chambless LE, Prineas RJ, Evans GW, Heiss G., Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Hypertension 2003 42 1106 1111. doi: 10.1161/01.HYP.0000100444.71069.73
50. Thomas JA, Marks BH., Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978 41 233 243